• 1/2008-Present: Director Clinical Research, Saint Mary’s Health Care
• 1/2008-Present: Director MSU MDA/ALS Clinic, Grand Rapids MI
• 2008-Present: Associate Professor, Department of Neurology, Michigan State University
• 08/2005-12/31/2007: Chief, Neurology Service, Nashoba Valley Medical Center, Ayer MA
• 01/1993-6/2005: Director, ALS Clinical Service, Forbes Norris MDA/ALS Center,
  Department of Neurology, California Pacific Medical Center, San Francisco, CA
• 06/1989-12/1992: Staff Neurologist, Letterman US Army Hospital, San Francisco, CA

• 1984-1989, Neurology Residency, Letterman Army Medical Center

• B.S., McGill University, Montreal, Canada, Psychobiology, 1979
• M.D., New York Medical College, Medicine, 1984

• 2000 - Outstanding Physician Scientist Award, CPMC
• 1984 - Surgical Society Award of New York Medical College
• 1984 - American Medical Women’s Association
• 1984 - NYMC, MD, Surgery Award
• 1984 - NYMC, MD, Psychiatry Award
• 1984 - NYMC, MD, Rehabilitation Medicine Award
• 1983-84 - Alpha Omega Alpha
• 1983-84 - Rock Sleyster Scholarship for Research Endeavors in Psychiatry

The management of patients with chronic neurodegenerative disease, including respiratory and nutritional care and maintenance of quality of life.

• A Phase III Trial of Insulin Like Growth Factor-1 (IGF-1) in Patients with Amyotrophic Lateral Sclerosis (ALS).  08/01/03-07/31/07. Sponsor:  NIH.  Site Investigator. 
• Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis (ALS).  01/24/03 – 01/23/06. Sponsor:  Avecina, NIH.  Site Investigator. 
• A Randomized, Double-Blind, Placebo-Controlled, Stratified, Parallel-group, Multicenter, Dose-ranging Study of Four Oral Doses (1.0, 2.5, 7.5 and 15 mg given once daily) of TCH346 in Patients with Amyotrophic Lateral Sclerosis. Protocol # CTCH346A2211.  09/01/03 – 07/31/05. Sponsor: Novartis.   Sub-Investigator.
• Multicenter Study Using High Frequency Chest Wall Oscillation (HFCWO) to Reduce the Incidence and Duration of Pulmonary Complications in Patients with Amyotrophic Lateral Sclerosis (ALS).  06/15/03 – 06/14/04. Sponsor: Advanced Respiratory.  Site Investigator.
• A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects with Mild to Moderate Alzheimer’s Disease.  Sponsor: Fujisawa, 2004 --.  Site Investigator.
• A 24-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients with Severe Alzheimer’s Disease Followed by a 12-week Open-Label Extension Period.  Protocol # E2020-A001-315. 09/01/03 - 08/30/04.  Sponsor: Pfizer.  Site Investigator. 
• Specific Study Title: A Prospective, 20-Week, Open-Label, Single-Arm, Multicenter Study Evaluating the Efficacy and Safety of Exelon® (rivastigmine tartrate) 3-12 mg/day in Patients with Mild to Moderate Alzheimer’s Disease who are Responding Poorly to Aricept® (donepezil) Treatment.  Protocol # CENA713BUS13.  08/01/03 - 07/31/04. Sponsor: Novartis.  Site Investigator. 
• A Trial to Evaluate the Tolerability of the Herbal Dietary Supplement QR-334 in Subjects with         Excessive Salivary Secretions.  Protocol # QR-334-01.  06/06/03 – 12/31/04. Sponsor: Quigley Pharma, Inc.       Site Investigator. 
• Immunophenotypic Analysis and Viral Sequencing in Patients with Amyotrophic Lateral Sclerosis (ALS).  4/3/02-3/11/03.  Sponsor: NIH.  Sub-Investigator.
• A Pilot Study of Hope in ALS and Other Chronic Neurological Diseases.  09/03 ---.  Sponsor: CPMC Research Institute.  Principal Investigator.
• 1H Magnetic Resonance Spectroscopy Imaging, detection of upper motor neuron loss in ALS.  The overall goal of this study is to determine anatomical and chemical alterations in the brain produced by ALS.  CPMC Protocol #21.004P 08/98-01/03.  Sponsor: NIH, ALSA,  Co-Investigator.
• Immunophenotypic Analysis, Viral Sequencing and the Use of         Human Macrophages from Patients with Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) in the Development of a  Murine Model of ALS.  12/26/02 ---.  Sponsor: NIH.  Sub-Investigator.
• Phase III Trial of Minocycline in ALS. 10/03 -09/06. Sponsor: NIH.  Sub-Investigator.
  A pilot study of Safety and Tolerability of Delta 9-THC (Marinol) treatment for ALS.  CPMC Protocol #21.015P 03/01-03/02.  The goal of this project is to examine the safety and tolerability of Delta 9-THC in patients with ALS. Sponsor: CPMC Research Institute. Principal Investigator.
• Long-term and tolerability study of SR57746A in patients with amyotrophic lateral sclerosis. The overall goal of this study is to determine the tolerability and effectiveness in patients with ALS.  CPMC protocol #97.039P 06/97-01/02   Sponsor: Sanofi.  Co-Principal Investigator

• Mendoza M, Gelinas D et al, Inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis and other Motor Neuron Diseases, accepted for publication Sept. 2006.
• Lechtzin N, Gelinas D et al and the HFCWO study group.  Performance of an Instrument to measure change in dyspnea in patients with ALS, Muscle and Nerve, accepted for publication Aug. 2006.
• Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, et al.  Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS).  J Neuroimmunol 2005;159(102):215-24.
• Miller RG, Gelinas D, O’Connor, P.  Amyotrophic Lateral Sclerosis.  AAN Press Quality of Life Guide.  Demos Medical Publishing. 2004.
• Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al.  Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis.  Neurology 2004;62(10):1845-7.
• Ng AV, Miller RG, Gelinas D, Kent-Braun JA.  Functional Relationships of Central and Peripheral Muscle Alterations in Multiple Sclerosis.  Muscle & Nerve June 2004; 843-852.
• Rule RR, Suhy J, Schuff N, Gelinas DF, Miller RG, Weiner MW.  Reduced NAA in motor and non-motor brain regions in amyotrophic lateral sclerosis: a cross-sectional and longitudinal study.  Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(3):141-9.
• Gelinas DF.  Pulmonary Function Screening.  Seminars in Neurology 2003;23 (1):89-96.
• Gelinas DF, Miller RG.  Quality of Life and Psychosocial Aspects of Care of Patients with Amyotrophic Lateral Sclerosis.  Blue Books of Practical Neurology. Motor Neuron Disorders.  Edited by Pamela Shaw and Michael Strong. 2003; Chapter 19:465-484.
• Gelinas DF, Miller RG.  Quality of Life and Psychosocial Aspects of Care of Patients with Amyotrophic Lateral Sclerosis.  Blue Books of Practical Neurology. Motor Neuron Disorders.  Edited by Pamela Shaw and Michael Strong. 2003; Chapter 19:465-484.
• Gelinas DF.  Pulmonary Function Screening.  Seminars in Neurology 2003;23 (1):89-96.
• Suhy J, Miller RG, Rule R, Schuff N, Licht J, Dronsky V, Gelinas DF, Maudsley AA, Weiner MW.  Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI.  Neurology 58:773-779. 
• Suhy J, Miller RG, Rule R, Schuff N, Licht J, Dronsky V, Gelinas DF, Maudsley AA, Weiner MW.  Early detection and longitudinal changes in amyotrophic lateral sclerosis by 1H MRSI.  Neurology 58 (2002):773-779.
• Gelinas DF.  Respiratory Failure or Impairment in Amyotrophic Lateral Sclerosis, Curr Treat Opt Neurol 2001:133-138.
• Jackson CD, Rosenfeld J, Moore DH, Gelinas DF, et al.  A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients.  J Neurol Sci 191 (2001):75-78.
• Miller RG, Moore DH, Dronsky V, Bradley, Barohn R, Gelinas DF, et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy.  J Neurol Sci 191 (2001):127-131.
• Fanos JH, Gelinas DF, Miller RG.  “You have shown me my end”: attitudes toward presymptomatic testing for familial amyotrophic lateral sclerosis.  Am J Med Genet 2004:129A(3):248-53.Gelinas DF.   Effects of the early diagnosis of amyotrophic lateral sclerosis on the patient:  advantages.  ALS and other motor neuron disorders 2000; Suppl 1, S73-S74.